UBS Group AG Increases Position in Integra LifeSciences Holdings Corporation $IART

UBS Group AG raised its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 211.7% during the fourth quarter, HoldingsChannel reports. The firm owned 408,969 shares of the life sciences company’s stock after buying an additional 277,745 shares during the quarter. UBS Group AG’s holdings in Integra LifeSciences were worth $5,079,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Osaic Holdings Inc. increased its position in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares during the last quarter. Amundi grew its position in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after buying an additional 11,004 shares during the last quarter. Finally, State of Wyoming grew its position in shares of Integra LifeSciences by 84.0% in the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company’s stock valued at $159,000 after buying an additional 5,914 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IART has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Finally, Citigroup increased their target price on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a research report on Wednesday, May 6th. Three investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $12.75.

Integra LifeSciences Stock Down 1.8%

Shares of NASDAQ:IART opened at $15.12 on Friday. The stock has a market cap of $1.18 billion, a P/E ratio of -2.34, a P/E/G ratio of 1.07 and a beta of 1.08. The firm has a fifty day moving average price of $10.99 and a 200 day moving average price of $11.67. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. Integra LifeSciences Holdings Corporation has a 1-year low of $8.70 and a 1-year high of $16.49.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.